Disease Areas

Breast cancer

Niraparib-pembrolizumab combo may have benefit in ovarian, breast cancers (20/6/2019) ›Cardioprotective drugs can help avoid chemo disruption in some breast cancer patients (5/6/2019) ›Ribociclib plus hormone therapy prolongs survival of younger patients with advanced breast cancer (3/6/2019) ›Novartis' breast cancer treatment wins FDA approval (24/5/2019) ›Nipple-sparing mastectomy safe for more women with breast cancer (9/5/2019) ›Bioimpedance spectroscopy helps prevent breast cancer-related lymphedema progression (8/5/2019) ›Low-dose tamoxifen prevents recurrence of in situ breast cancer (3/5/2019) ›HER2 testing inaccessible for many women with breast cancer (2/5/2019) ›Promising strategy identifies triple-negative breast cancers that might respond to tamoxifen (23/4/2019) ›Surgery after systemic therapy tied to improved outcome of HER2+ advanced breast cancer (5/4/2019) ›Fulvestrant-anastrozole combo improves survival in metastatic breast cancer (27/3/2019) ›Fewer benign biopsies with digital breast tomosynthesis (26/3/2019) ›St. Gallen Consensus - Primary surgery: margins (23/3/2019) ›St. Gallen Consensus - Skin and nipple sparing surgery: still a matter of debate (23/3/2019) ›St. Gallen Consensus - Surgery of the axilla: indications decrease (23/3/2019) ›St. Gallen Consensus - DCIS: de-escalation of (adjuvant) therapy (23/3/2019) ›Letter from the editor (23/3/2019) ›Selection of patients for neoadjuvant chemotherapy treatment based on oncotype recurrence score in luminal breast cancer (23/3/2019) ›New prognostic biomarkers for survival breast cancer (23/3/2019) ›Discordance of biomarkers in multifocal and lymph node positive breast cancer (23/3/2019) ›History of the consensus meeting (23/3/2019) ›What is the clinical benefit of treatment of patients with early breast cancer? (23/3/2019) ›Extrapolating data from clinical trials as we treat patients in real life (23/3/2019) ›St. Gallen Consensus - Life style (23/3/2019) ›St. Gallen Consensus - Pregnancy after breast cancer (23/3/2019) ›St. Gallen Consensus - Germ-line mutations (23/3/2019) ›St. Gallen Consensus - Bisphosphonates and denosumab (23/3/2019) ›St. Gallen Consensus - Adjuvant therapy in triple-negative breast cancer (23/3/2019) ›St. Gallen Consensus - Adjuvant Her2-targeted therapy (23/3/2019) ›St. Gallen Consensus - Endocrine therapy in postmenopausal patients: a graded approach (23/3/2019) ›St. Gallen Consensus - Endocrine therapy in premenopausal patients (23/3/2019) ›St. Gallen Consensus - Adjuvant chemotherapy after neoadjuvant chemotherapy? Going beyond EMA/FDA (23/3/2019) ›St. Gallen Consensus - Neoadjuvant therapy and residual disease (23/3/2019) ›St. Gallen Consensus - Gene expression signatures (23/3/2019) ›Adjuvant and neoadjuvant therapy: principles and practical considerations (23/3/2019) ›Screening ultrasonography does not improve breast-cancer detection (21/3/2019) ›Breast cancer risk tied to DDT varies by exposure timing (14/3/2019) ›Heart-failure risk increased after adjuvant trastuzumab for breast cancer (28/2/2019) ›Long-lasting menopause symptoms may be tied to slightly higher breast cancer risk (17/1/2019) ›Task force adds aromatase inhibitors to advice on breast cancer chemoprevention in high-risk women (15/1/2019) ›

Cancer

Checkpoint inhibitors may be retried after immune adverse event, with close monitoring (12/6/2019) ›Only 13% of patients eligible for checkpoint inhibitors respond to them (13/5/2019) ›Numerous new anticancer drugs not proven superior to standard of care (9/5/2019) ›Molecular profiling identifies potential treatment targets in many hard-to-treat pediatric cancers (7/5/2019) ›High-dose, single-fraction SBRT likely effective for non-spine bone metastases (2/5/2019) ›Adverse events common with PD-1 and PD-L1 inhibitors (1/5/2019) ›Many young cancer patients regret initial treatment decisions (23/4/2019) ›Study of AYA-cancer survivors can guide surveillance for new primary neoplasms (28/2/2019) ›Tisotumab vedotin shows some promise in early trial of solid tumors (19/2/2019) ›Hyperthermic intraperitoneal chemo relatively safe for treating metastases (7/2/2019) ›Hypothermic intraperitoneal chemo relatively safe for treating metastases (31/1/2019) ›Tumor markers limit imaging need in germ-cell tumor surveillance (16/1/2019) ›Life expectancy predicts benefit of immune-checkpoint inhibitors (15/1/2019) ›Brain metastases, lung cancer and interstitial lung disease (19/9/2018) ›ALK inhibition, guidelines, liquid biopsies, and immunotherapy (19/9/2018) ›Cancer risk in IBD associated with age and recent immunomodulator use (19/9/2018) ›EGFR-targeted treatments (19/9/2018) ›Malignancies occur infrequently with tofacitinib (17/2/2018) ›Long-term risk of advanced neoplasia after colonic low-grade dysplasia in IBD (17/2/2018) ›SLC12A2 potential marker of dysplasia associated to inflammation in UC (17/2/2018) ›Shallow whole-genome sequencing predicts future cancer risk of LGD in UC (17/2/2018) ›Significantly increased risk of CRC and/or HGD after appendectomy in UC (17/2/2018) ›

Crohn's disease

Early endoscopic remission linked to altered course of Crohn's disease (29/5/2019) ›Machine-learning models help predict remission in Crohn's (23/5/2019) ›Ustekinumab as maintenance therapy and with shortened interval (14/5/2019) ›Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease (14/5/2019) ›Relapse after withdrawal of thiopurines (14/5/2019) ›Early remission of Crohn’s disease prevents progression (14/5/2019) ›Proactive adalimumab trough measurements increase corticosteroid-free clinical remission (14/5/2019) ›Efficacy and safety of biosimilars (14/5/2019) ›The costs and benefits of biologicals (14/5/2019) ›Infliximab retreatment in luminal Crohn’s disease (14/5/2019) ›Pathogenesis (14/5/2019) ›Immune cells and microbes: a happy marriage? (14/5/2019) ›Moving towards new therapeutic options (14/5/2019) ›ZNF133 associated with infliximab response (14/5/2019) ›Network analysis of GWAS (14/5/2019) ›Gene expression signature predicts non-response (14/5/2019) ›Ustekinumab beneficial in refractory Crohn's disease in real world (30/4/2019) ›MR enterography best identifies fibrotic vs inflammatory strictures in Crohn's disease (23/4/2019) ›Infliximab biosimilar CT-P13 noninferior in active Crohn's disease (9/4/2019) ›T cell clonal expansion linked to postop recurrence of Crohn's in smokers (11/3/2019) ›New risk score helps predict intra-abdominal abscess in Crohn's disease (5/3/2019) ›Treg cells show promise as immunotherapy for Crohn's disease (13/2/2019) ›Adding vedolizumab to steroids may boost response, remission in Crohn's disease (30/1/2019) ›Postpartum substance abuse, mood disorders more common with IBD (25/1/2019) ›Early and significant effects with upadacitinib induction treatment (17/2/2018) ›SHP647 is efficacious and well-tolerated in CD (17/2/2018) ›Comparative effectiveness of vedolizumab and ustekinumab in CD (17/2/2018) ›Vedolizumab induces endoscopic remission and healing in refractory CD (17/2/2018) ›

Inflammatory bowel disease

Overall diet quality in many with IBS is poor (23/5/2019) ›Hypoalbuminemia linked to worse outcomes after IBD surgery (15/5/2019) ›The costs and benefits of biologicals (14/5/2019) ›IBD risk of treatment with IL-17 antagonists (14/5/2019) ›Safety of thiopurine + allopurinol vs thiopurine monotherapy (14/5/2019) ›Glycans as novel immunomodulators in inflammatory bowel disease (14/5/2019) ›Topical review (14/5/2019) ›Complementary and alternative medicine associated with chronic fatigue and lower QoL (14/5/2019) ›Novel host-microbiome interactions in inflammatory bowel disease (14/5/2019) ›Microbial composition and psychological wellbeing (14/5/2019) ›Novel test predicts IBD course at diagnosis (13/5/2019) ›Breath analysis shows promise in distinguishing IBD types (9/5/2019) ›Immunosuppressants found safe for IBD patients with cancer history (30/4/2019) ›Sleeve gastrectomy may be safer than gastric bypass for IBD patients (28/2/2019) ›Azathioprine ups pancreatitis risk in pediatric IBD (31/1/2019) ›Postpartum substance abuse, mood disorders more common with IBD (25/1/2019) ›Advanced endoscopic techniques improve IBD assessment (8/1/2019) ›Cancer risk in IBD associated with age and recent immunomodulator use (19/9/2018) ›Clinical effect of vedolizumab on articular manifestations spondyloarthritis associated with IBD (16/6/2018) ›Quiescent disease, characteristics and biomarker correlations (20/2/2018) ›Combining new drugs with different mechanisms (17/2/2018) ›Genetic predisposition for gut barrier dysfunction (17/2/2018) ›ILC1 distribution predicts response to ustekinumab (17/2/2018) ›Integration of “omics” and potential for clinical practice (17/2/2018) ›Targeting early disease: lessons from rheumatoid arthritis (17/2/2018) ›Higher rates of remission and healing with vedolizumab vs. TNF antagonist (17/2/2018) ›Overall manageable safety profile of tofacitinib in long-term use (17/2/2018) ›Vedolizumab in anti-TNF-naïve IBD patients and safety profile (17/2/2018) ›Higher colectomy rate with infliximab vs. conventional therapies in more severe UC (17/2/2018) ›Central role of IL-23 in molecular resistance to anti-TNF therapy (17/2/2018) ›Shallow whole-genome sequencing predicts future cancer risk of LGD in UC (17/2/2018) ›Long-term safety profile of adalimumab (17/2/2018) ›SLC12A2 potential marker of dysplasia associated to inflammation in UC (17/2/2018) ›Long-term risk of advanced neoplasia after colonic low-grade dysplasia in IBD (17/2/2018) ›Enhanced post-operative recovery pathways for IBD patients (17/2/2018) ›Significantly increased risk of CRC and/or HGD after appendectomy in UC (17/2/2018) ›Malignancies occur infrequently with tofacitinib (17/2/2018) ›Diagnostic techniques for IBD: the ECCO-ESGAR Guidelines (17/2/2018) ›Significant reduction of emergency stoma surgeries for CD (17/2/2018) ›

Lung cancer

Lung cancer radiotherapy tied to higher cardiac mortality (18/6/2019) ›Broadening eligibility for lung cancer trials could have huge impact (5/6/2019) ›Pembrolizumab quadruples survival in selected advanced non-small cell lung cancer patients (3/6/2019) ›Atezolizumab added to chemo ups survival in lung cancer (31/5/2019) ›Longer lung-cancer-screening intervals may sometimes be OK (27/5/2019) ›Vein-first ligation in lung-cancer surgery may increase survival (14/5/2019) ›New technique for minimally invasive lung cancer surgery promising (10/5/2019) ›Higher radiation doses tied to increased longevity in node-negative lung cancer (30/4/2019) ›Deep-learning model may help predict NSCLC outcomes, survival (30/4/2019) ›Lung-cancer survival worse in patients with pulmonary fibrosis (25/4/2019) ›Electromagnetic navigation: an instant hit? (11/4/2019) ›Comprehensive profiling in localised stage lung cancer (11/4/2019) ›Post-study immunotherapy confounds primary survival outcome (11/4/2019) ›Survival benefit persists despite post-discontinuation therapy (11/4/2019) ›Immunotherapy in elderly: diverse findings across the globe (11/4/2019) ›Next-generation sequencing assay detects genetic variants driving cancer, resistance in NSCLC (2/4/2019) ›Pembrolizumab may help some with advanced non-small-cell lung cancer (2/4/2019) ›Cranial irradiation doesn't boost survival in locally advanced lung cancer (26/3/2019) ›Lung-cancer screens effective in asbestos-exposed smokers (14/3/2019) ›Liquid biopsy on par with tissue testing in advanced lung cancer (5/3/2019) ›Stereotactic ablative radiotherapy tops for inoperable early non-small-cell lung cancer (21/2/2019) ›It's never too late to quit smoking before lung surgery (16/1/2019) ›Lung cancer screening complications may be higher than expected (14/1/2019) ›Interview with IASCL President (26/9/2018) ›Small-cell lung cancer circulating tumour cell derived explants (26/9/2018) ›Effects of dose modifications on safety and efficacy of dacomitinib for EGFR-mutant non-small-cell lung cancer (26/9/2018) ›Central nervous system activity of ramucirumab + osimertinib in patients with advanced T790M-positive EGFR-mutant non-small-cell lung cancer (26/9/2018) ›Prognostic value of distant organ-specific metastases in newly diagnosed lung neuroendocrine tumours (26/9/2018) ›Spread through air spaces is prognostic in lung neuroendocrine tumours (26/9/2018) ›Entrectinib treatment in patients with ROS1+ NSCLC (26/9/2018) ›Angiogenic and stromal biomarkers in malignant mesothelioma (26/9/2018) ›Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer (26/9/2018) ›Osimertinib and RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement (26/9/2018) ›Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC (26/9/2018) ›Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer (26/9/2018) ›Next generation immunotherapy in non-small-cell lung cancer (26/9/2018) ›Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer (26/9/2018) ›Combination therapies: Where are we in 2018? (26/9/2018) ›Unmet needs in surgical management of malignant pleural mesothelioma (26/9/2018) ›PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib (26/9/2018) ›Crizotinib-treated ALK IHC-positive advanced NSCLC is associated with an unfavourable prognosis when FISH negative (26/9/2018) ›Benefits of chest CT screening (26/9/2018) ›New standard of care in extensive-stage small-cell lung cancer (26/9/2018) ›Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer (26/9/2018) ›Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer (26/9/2018) ›No progression-free survival benefit with nintedanib plus pemetrexed/cisplatin for malignant pleural mesothelioma of epithelial subtype (26/9/2018) ›

Psoriasis

Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies (18/6/2019) ›Reduction in coronary artery disease in psoriasis patients treated with biologic therapies (18/6/2019) ›Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis? (18/6/2019) ›Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies (18/6/2019) ›ABP501 Biosimilar for adalimumab: What you need to know (18/6/2019) ›Switching infliximab biosimilars safe in treating chronic plaque psoriasis (18/6/2019) ›Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis (18/6/2019) ›Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease in patients with moderate-to-severe plaque psoriasis (18/6/2019) ›Treatment goals in psoriasis (18/6/2019) ›Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (18/6/2019) ›Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity (18/6/2019) ›Favourable safety profile of long-term use of ixekizumab (18/6/2019) ›Advances in target-oriented therapy: psoriatic arthritis (18/6/2019) ›Atopic dermatitis and psoriasis: on a spectrum? (18/6/2019) ›Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis (18/6/2019) ›Small molecules, apremilast, and TYK2 (18/6/2019) ›Novel selective IL-23 blocker highly effective over 2 years (10/6/2019) ›The role of the gut-skin axis in dermatology, specifically psoriasis (10/6/2019) ›Etanercept biosimilar shows preliminary efficacy in psoriasis and psoriatic arthritis (10/6/2019) ›Infliximab associated with a 3-fold risk of serious infections (10/6/2019) ›Plaque psoriasis – Efficacy of guselkumab (25/4/2019) ›Serlopitant reduces pruritus associated with psoriasis (25/4/2019) ›Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis (25/4/2019) ›Secukinumab maintains improvements in psoriasis through 5 years of treatment (25/4/2019) ›Psoriasis and Biologics: The Beat Goes On (25/4/2019) ›Oral therapeutics, supersaturation and excimer laser (20/2/2018) ›Living in the golden age of psoriasis and atopic dermatitis therapies (20/2/2018) ›Biologics in psoriasis and new selective IL-23 blockers (20/2/2018) ›Psoriasis management online? (20/2/2018) ›Intralesional cryosurgery and itching in psoriasis (20/2/2018) ›Improvement in impact of genital psoriasis on sexual activity with use of ixekizumab (20/2/2018) ›Better gastrointestinal tolerability with biologics than the conventional therapy (20/2/2018) ›Psoriasis: Selective IL-23 blocker, analysis of VOYAGE-2, dual IL-17 inhibitor and ustekinumab (20/2/2018) ›

Subscribe for free ›

Stay up-to-date with Medicom. Subscribe to the Medicom Conference Reports and newsletter.

"The Medicom Conference Reports offer an excellent summary of the most important developments and presentations in medicine. They are well written and include the most recent references. Very informative and highly recommended."

Editor Medicom Conference Report series in Pulmonology

  • Prof dr P.N. Richard Dekhuijzen,
  • MD, PhD
  • Radboud university medical center
  • Dept. of Pulmonary Diseases

About us ›

Medicom provides the highest quality medical information and tools to international medical professionals.